Publications

1. Farr JN, Khosla S, Miyabara Y, Miller VM, Kearns AE. Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. J Clin Endocrinol Metab. 2013 Feb; 98(2):E249-57. Epub 2013 Jan 15. 2297879
   View PubMed
2. Dy BM, Grant CS, Wermers RA, Kearns AE, Huebner M, Harmsen WS, Thompson GB, Farley DR, Richards ML. Changes in bone mineral density after surgical intervention for primary hyperparathyroidism. Surgery. 2012 Dec; 152(6):1051-8. Epub 2012 Oct 03. 2274745
   View PubMed
3. Miyabara Y, Holmes D 3rd, Camp J, Miller VM, Kearns AE. Comparison of calibrated and uncalibrated bone mineral density by CT to DEXA in menopausal women. Climacteric. 2012 Aug; 15(4):374-81. Epub 2011 Dec 17. 2261910
   View PubMed
4. Espiritu RP, Kearns AE, Vickers KS, Grant C, Ryu E, Wermers RA. Depression in primary hyperparathyroidism: prevalence and benefit of surgery. J Clin Endocrinol Metab. 2011 Nov; 96(11):E1737-45. Epub 2011 Sep 14. 2190627
   View PubMed
5. Miyabara Y, Camp J, Holmes D 3rd, Lahr B, Bailey K, Miller VM, Kearns AE. Coronary arterial calcification and thoracic spine mineral density in early menopause. Climacteric. 2011 Aug; 14(4):438-44. Epub 2011 Jan 25. 2187724
   View PubMed
6. Davidge Pitts CJ, Kearns AE. Update on medications with adverse skeletal effects. Mayo Clin Proc. 2011 Apr; 86(4):338-43; quiz 343. Epub 2011 Mar 9. 2323419
   View PubMed
7. Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, Kearns A, Thomas T, Boyd SK, Boutroy S, Bogado C, Majumdar S, Fan M, Libanati C, Zanchetta J. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010 Aug; 25(8):1886-94. 2116317
   View PubMed
8. Kearns AE, Northfelt DW, Dueck AC, Atherton PJ, Dakhil SR, Rowland KM Jr, Fuloria J, Flynn PJ, Dentchev T, Loprinzi CL. Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8. Support Care Cancer. 2010 Mar; 18(3):321-8. Epub 2009 May 27. 1944172
   View PubMed
9. Melton LJ 3rd, Kearns AE, Atkinson EJ, Bolander ME, Achenbach SJ, Huddleston JM, Therneau TM, Leibson CL. Secular trends in hip fracture incidence and recurrence. Osteoporos Int. 2009 May; 20(5):687-94. Epub 2008 Sep 17. 1909082
   View PubMed
10. Kearns AE, Kallmes DF. Osteoporosis primer for the vertebroplasty practitioner: expanding the focus beyond needles and cement. AJNR Am J Neuroradiol. 2008 Nov; 29(10):1816-22. Epub 2008 Sep 03. 1915697
    View PubMed
11. Chow JT, Khosla S, Melton LJ 3rd, Atkinson EJ, Camp JJ, Kearns AE. Abdominal aortic calcification, BMD, and bone microstructure: a population-based study. J Bone Miner Res. 2008 Oct; 23(10):1601-12. 1901870
    View PubMed
12. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008 Apr; 29(2):155-92. Epub 2007 Dec 05. 1883264
    View PubMed
13. Wermers RA, Kearns AE, Jenkins GD, Melton LJ 3rd. Incidence and clinical spectrum of thiazide-associated hypercalcemia. Am J Med. 2007 Oct; 120(10):911.e9-15. Epub 2007 Apr 16. 1844444
    View PubMed
14. Hallanger Johnson JE, Kearns AE, Doran PM, Khoo TK, Wermers RA. Fluoride-related bone disease associated with habitual tea consumption. Mayo Clin Proc. 2007 Jun; 82(6):719-24. 1830722
    View PubMed
15. From AM, Hyder JA, Kearns AM, Bailey KR, Pellikka PA. Relationship between low bone mineral density and exercise-induced myocardial ischemia. Mayo Clin Proc. 2007 Jun; 82(6):679-85. 1830727
    View PubMed
16. Wermers RA, Hurley DL, Kearns AE. Osteoporosis associated with megestrol acetate. Mayo Clin Proc. 2004 Dec; 79(12):1557-61. 1674494
    View PubMed
17. Kearns AE, Khosla S. Potential anabolic effects of androgens on bone. Mayo Clin Proc. 2004 Apr; 79(4 Suppl S):S14-8. 1641334
    View PubMed
18. Modder UI, Sanyal A, Kearns AE, Sibonga JD, Nishihara E, Xu J, O'Malley BW, Ritman EL, Riggs BL, Spelsberg TC, Khosla S. Effects of loss of steroid receptor coactivator-1 on the skeletal response to estrogen in mice. Endocrinology. 2004 Feb; 145(2):913-21. Epub 2003 Oct 16. 1517964
    View PubMed
19. Kearns AE. Primary hyperparathyroidism: is there anything new? Compr Ther. 2004; 30(2):105-10. 1669461
    View PubMed
20. Kearns AE, Thompson GB. Medical and surgical management of hyperparathyroidism. Mayo Clin Proc. 2002 Jan; 77(1):87-91. 1007924
    View PubMed
21. Kearns AE, Donohue MM, Sanyal B, Demay MB. Cloning and characterization of a novel protein kinase that impairs osteoblast differentiation in vitro. J Biol Chem. 2001 Nov 9; 276(45):42213-8. Epub 2001 Aug 10. 1006879
    View PubMed
22. Kearns AE, Demay MB. BMP-2 induces expression of activin BA and fillistatin in vitro. J Cell Biochem, 2000; 79:80-88. 1892868
    
23. Kearns AE, Goff DC, Hayden DL, Daniels GH. Risperidone-associated hyperprolactinemina. Endo Practice, 2000; 6:425-429. 1892869
    
24. Kearns AE, Goto K, Gianakakos G, Lippmann W, Demay MB. Transcriptional repression of the rat osteocalcin gene: role of two intronic CCTCCT motifs. Endocrinology. 1999 Sep; 140(9):4120-6. 1892978
    View PubMed
25. Kearns AE, Vertel BM, Schwartz NB. Topography of glycosylation and UDP-xylose production. J Biol Chem. 1993 May 25; 268(15):11097-104. 1028894
    View PubMed
26. Vertel BM, Walters LM, Flay N, Kearns AE, Schwartz NB. Xylosylation is an endoplasmic reticulum to Golgi event. J Biol Chem. 1993 May 25; 268(15):11105-12. 1028719
    View PubMed
27. Ng K, D'Souza M, Callahan L, Geller DH, Kearns AE, Lyle S, Schwartz NB. Synthesis and utilization of a nonhydrolyzable phosphoadenosine phosphosulfate analog. Anal Biochem. 1991 Oct; 198(1):60-7. 1036615
    View PubMed
28. Kearns AE, Campbell SC, Westley J, Schwartz NB. Initiation of chondroitin sulfate biosynthesis: a kinetic analysis of UDP-D-xylose: core protein beta-D-xylosyltransferase. Biochemistry. 1991 Jul 30; 30(30):7477-83. 1036616
    View PubMed